Flexion Therapeutics (NASDAQ:FLXN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday, Zacks.com reports.

According to Zacks, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. “

Other research analysts also recently issued research reports about the stock. BTIG Research began coverage on shares of Flexion Therapeutics in a report on Monday, November 25th. They issued a “buy” rating and a $27.00 target price on the stock. ValuEngine cut shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, October 25th. Northland Securities set a $20.00 target price on shares of Flexion Therapeutics and gave the company a “buy” rating in a report on Tuesday, September 10th. Craig Hallum began coverage on shares of Flexion Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $24.00 price target on the stock. Finally, BidaskClub upgraded shares of Flexion Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $24.00.

FLXN traded up $0.79 on Tuesday, hitting $20.95. 1,263,253 shares of the company were exchanged, compared to its average volume of 631,991. The company has a market cap of $799.77 million, a price-to-earnings ratio of -4.67 and a beta of 1.41. The company has a current ratio of 5.96, a quick ratio of 5.57 and a debt-to-equity ratio of 27.76. The firm has a 50-day moving average price of $17.05 and a two-hundred day moving average price of $13.29. Flexion Therapeutics has a twelve month low of $8.76 and a twelve month high of $21.05.

Flexion Therapeutics (NASDAQ:FLXN) last issued its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($1.00) earnings per share for the quarter, topping the consensus estimate of ($1.01) by $0.01. The business had revenue of $21.79 million for the quarter, compared to analyst estimates of $18.85 million. Flexion Therapeutics had a negative return on equity of 271.22% and a negative net margin of 266.51%. Equities analysts expect that Flexion Therapeutics will post -4.07 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. California State Teachers Retirement System lifted its position in shares of Flexion Therapeutics by 1.2% in the 3rd quarter. California State Teachers Retirement System now owns 52,632 shares of the specialty pharmaceutical company’s stock worth $721,000 after purchasing an additional 628 shares during the period. Campbell Capital Management Inc. lifted its position in shares of Flexion Therapeutics by 0.8% in the 3rd quarter. Campbell Capital Management Inc. now owns 130,622 shares of the specialty pharmaceutical company’s stock worth $1,790,000 after purchasing an additional 1,000 shares during the period. Claro Advisors LLC lifted its position in shares of Flexion Therapeutics by 5.4% in the 3rd quarter. Claro Advisors LLC now owns 23,300 shares of the specialty pharmaceutical company’s stock worth $319,000 after purchasing an additional 1,200 shares during the period. Rhumbline Advisers lifted its position in shares of Flexion Therapeutics by 2.6% in the 3rd quarter. Rhumbline Advisers now owns 47,659 shares of the specialty pharmaceutical company’s stock worth $653,000 after purchasing an additional 1,202 shares during the period. Finally, Northern Trust Corp lifted its position in shares of Flexion Therapeutics by 0.3% in the 2nd quarter. Northern Trust Corp now owns 448,993 shares of the specialty pharmaceutical company’s stock worth $5,522,000 after purchasing an additional 1,529 shares during the period. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

Further Reading: How to interpret a stock’s beta number

Get a free copy of the Zacks research report on Flexion Therapeutics (FLXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.